IL-5 Recombinant Protein Cat. No.: 11-122

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Rabbit
SOURCE SPECIES:HEK293 cells
SEQUENCE:Met 20 - Ser 134
FUSION TAG:His Tag
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 15.2 kDa. The protein migrates as 15 kDa and 16-20 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
psi-iconProperties
PURITY:>90% as determined by SDS-PAGE.
PREDICTED MOLECULAR WEIGHT:15.2 kDa
PHYSICAL STATE:Lyophilized
BUFFER:PBS, pH7.4
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:IL-5,TRF,IL5,Interleukin-5
ACCESSION NO.:XP_002710247.1
OFFICIAL SYMBOL:IL5
GENE ID:100358075
psi-iconBackground and References
BACKGROUND:Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.
REFERENCES:1) Milburn MV, et al. 1993. Nature. 363(6425):172-6.
2) Shen HH, et al. 2003. J Immunol. 170(6):3296-305.
3) Sanderson CJ, et al. 1992. Blood. 79 (12): 3101–9.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.